Travere Therapeutics (TVTX) Accumulated Expenses (2011 - 2026)

Travere Therapeutics has reported Accumulated Expenses for 16 years, with the latest figure at $104.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 35.4% year-over-year to $104.4 million; the trailing twelve-month figure through Mar 2026 stood at $104.4 million (up 35.4% YoY), and the FY2025 full-year result was $126.0 million, up 46.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $104.4 million, down from $126.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $139.6 million in Q1 2024, with the low at $69.2 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $94.7 million across 5 years, with a median of $88.4 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 62.75% — and 2025, when it tumbled 44.76%.
• Travere Therapeutics' Accumulated Expenses stood at $95.7 million in 2022, then climbed by 24.28% to $119.0 million in 2023, then fell by 27.7% to $86.0 million in 2024, then jumped by 46.5% to $126.0 million in 2025, then decreased by 17.16% to $104.4 million in 2026.
• The last three Accumulated Expenses figures came in at $104.4 million (Q1 2026), $126.0 million (Q4 2025), and $105.8 million (Q3 2025), per Business Quant data.